

BIO DEUTSCHLAND

European Business Development Conference

7 – 8 October 2014 | Dresden | Germany

Karsten Henco

Dr Karsten Henco, 62, serves as Partner and Chairman of the Board of HS LifeSciences GmbH, Düsseldorf, Germany. He also acts as CEO of Qlaym GmbH and Qlaym Healthcare AG. Until July 2007 he acted as CEO of U3 Pharma AG, Munich. From Evotec BioSystems AG's inception in 1993 until July 1, 2001 Dr Henco was Managing Director and CEO of the company. Before joining EVOTEC he served as Managing Partner of QIAGEN. Dr Henco co-founded QIAGEN GmbH and its subsidiary, QIAGEN, Inc. (now QIAGEN NV) in 1985. From 1982 until 1985 Dr Henco worked at BASF AG in Ludwigshafen. Dr Henco studied biochemistry at the University of Hanover, Hanover Medical School, Technische Hochschule Darmstadt (Germany) and the University of Zurich.

Dr. Henco is Member or Chairman of several other Boards: Max Planck Innovation GmbH, Munich, QureInvest II SICAR, Luxemburg, PAREQ GmbH, Düsseldorf, CT Atlantic AG, Zurich, MedoDerm GmbH, Mainz, Ethris AG, Munich and Transimmune Inc. New Haven, USA. He serves as an advisor for the HighTech Gründerfonds on behalf of the German Minister of commerce.

Dr. Henco is co-founder or co-founding investor of several biotech companies in Germany, USA, Canada and Austria such as Qiagen NV, Evotec AG, NewLab AG, Coley Pharmaceuticals Inc, U3 Pharma AG, Neurimmune Therapeutics AG, Zurich, Switzerland, Medesso GmbH, CT Atlantic AG, HS LifeSciences AG and QureInvest II SICAR and its portfolio companies.